These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35072888)

  • 41. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial.
    Frith PA; Ashmawi S; Krishnamurthy S; Gurgun A; Hristoskova S; Pilipovic V; Hamann AM; Backer A; Olsson P; Kostikas K; Diaz DV;
    Respirology; 2018 Dec; 23(12):1152-1159. PubMed ID: 30074294
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Triple Therapy with Mometasone/Indacaterol/Glycopyrronium or Doubling the ICS/LABA Dose in GINA Step 4: IRIDIUM Analyses.
    van Zyl-Smit RN; Kerstjens HAM; Maspero J; Tanase AM; Lawrence D; Mezzi K; D'Andrea P; Chapman KR
    Pulm Ther; 2023 Sep; 9(3):395-409. PubMed ID: 37526856
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD.
    Chan MC; Tan EC; Yang MC
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1079-1088. PubMed ID: 29670344
    [TBL] [Abstract][Full Text] [Related]  

  • 44. QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease.
    Frampton JE
    Drugs; 2014 Mar; 74(4):465-88. PubMed ID: 24604791
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice - Results of the Non-Interventional DETECT Study.
    Plate T; Friedrich FW; Beier J
    Int J Chron Obstruct Pulmon Dis; 2020; 15():1335-1347. PubMed ID: 32606643
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Population pharmacokinetics of IND/GLY (indacaterol/glycopyrronium) in COPD patients.
    Demin I; Bartels C; Graham G; Bieth B; Gautier A; Tillmann HC; Sechaud R
    Int J Clin Pharmacol Ther; 2016 Jun; 54(6):405-15. PubMed ID: 27049057
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal.
    Reza Maleki-Yazdi M; Molimard M; Keininger DL; Gruenberger JB; Carrasco J; Pitotti C; Sauvage E; Chehab S; Price D
    Appl Health Econ Health Policy; 2016 Oct; 14(5):579-94. PubMed ID: 27516088
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life.
    Rossi A; Zanardi E; Poletti V; Cazzola M
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1383-92. PubMed ID: 26229457
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Real-life effectiveness of indacaterol/glycopyrronium/mometasone for symptomatic relief of cough after switching from inhaled corticosteroid/long-acting β
    Niimi A; Kanemitsu Y; Tajiri T; Sumi K; Mikami T; Kondo N
    ERJ Open Res; 2023 Mar; 9(2):. PubMed ID: 37009022
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Fixed combination of mometasone, indacaterol, glycopyrronium for the treatment of severe asthma : Enerzair® Breezhaler®].
    Louis R; Bougard N; Louis G; Pétré B; Schleich F
    Rev Med Liege; 2021 Oct; 76(10):768-772. PubMed ID: 34632748
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.
    Ulrik CS
    Int J Chron Obstruct Pulmon Dis; 2014; 9():331-8. PubMed ID: 24729699
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Indacaterol/glycopyrronium affects lung function and cardiovascular events in patients with chronic obstructive pulmonary diseases: A meta-analysis.
    Zhang Q; Zhang H; Wang J; Ruan Z; Dai Y; Xia Z; Lv Q
    Heart Lung; 2021; 50(4):532-541. PubMed ID: 33865004
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
    Wedzicha JA; Banerji D; Chapman KR; Vestbo J; Roche N; Ayers RT; Thach C; Fogel R; Patalano F; Vogelmeier CF;
    N Engl J Med; 2016 Jun; 374(23):2222-34. PubMed ID: 27181606
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjects.
    Vaidya SS; Khindri S; Calder N; Machineni S; Hara H; Majumdar T; Febbraro S; Fuhr R; Woessner R
    Pulm Pharmacol Ther; 2016 Apr; 37():30-6. PubMed ID: 26845343
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serious Asthma Outcomes and Asthma Exacerbations with Maintenance on Inhaled Corticosteroid (Mometasone Furoate)/Long-Acting Beta Agonist (Formoterol) Combination Compared to Step Down to Mometasone Monotherapy.
    Weinstein CLJ; Ryan N; Zhang X; Shekar T; Gates D; Lane SJ; Agache I; Nathan RA;
    J Allergy Clin Immunol Pract; 2020 May; 8(5):1634-1644.e1. PubMed ID: 31981733
    [TBL] [Abstract][Full Text] [Related]  

  • 56. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
    Mahler DA; Gifford AH; Satti A; Jessop N; Eckert JH; D'Andrea P; Mota F; Banerjee R
    Respir Med; 2016 Jun; 115():39-45. PubMed ID: 27215502
    [TBL] [Abstract][Full Text] [Related]  

  • 58. GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.
    Worth H; Buhl R; Criée CP; Kardos P; Lossi NS; Vogelmeier CF
    Respir Med; 2017 Oct; 131():77-84. PubMed ID: 28947047
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial.
    Beasley RW; Donohue JF; Mehta R; Nelson HS; Clay M; Moton A; Kim HJ; Hederer BM
    BMJ Open; 2015 Feb; 5(2):e006131. PubMed ID: 25649209
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease.
    Muraki M; Kunita Y; Shirahase K; Yamazaki R; Hanada S; Sawaguchi H; Tohda Y
    BMC Pulm Med; 2021 Jan; 21(1):26. PubMed ID: 33441146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.